Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | AATF |
| Gene Name: | AATF |
| Protein Full Name: | Protein AATF |
| Alias: | Apoptosis antagonizing transcription factor; Apoptosis-antagonizing transcription factor; CHE1; CHE-1; DED |
| Mass (Da): | 63133 |
| Number AA: | 560 |
| UniProt ID: | Q9NY61 |
| Locus ID: | 26574 |
| COSMIC ID: | AATF |
| Gene location on chromosome: | 17q12 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 7055 |
| Percent of cancer specimens with mutations: | 0.3 |
| Normal role description: | AATF functions as a general inhibitor of the histone deacetylase HDAC1. Binding of AATF to the pocket region of RB1 may displace HDAC1 from RB1/E2F complexes, leading to activation of E2F target genes and cell cycle progression. AATF was also identified as an interacting partner with the protein kinase MAP3K12/DLK, which mediates induction of cell apoptosis. Overproduction of AATF interferes with MAP3K12 induced apoptosis. AATF contains a leucine zipper, which is a characteristic motif of transcription factors, and it has been shown to exhibit strong transactivation activity when fused to Gal4 DNA binding domain. |
| Commentary on involvement of protein in cancer: | Several polymorphisms have been identified, but none of them has shown any association with any disease. AATF plays a major role in immortalization of leukemic cells through up-regulation of Bcl2 gene expression. However, displacement of HDAC1 from SP1 bound to the CDKN1A promoter leads to increased expression of this CDK inhibitor and blocks cell cycle progression. |